Program
Boostrix
Also written as “Boostrix™”, “Boostrix®” and “Tdap vaccine”.
Its studies are mostly in Tetanus · Diphtheria · Whooping Cough · Respiratory Syncytial Virus Infections · Herpes Zoster, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 200 open or running | phase 4since Jan 25, 2006 | Jan 25, 2006 | none ahead |
| Changchun BCHT Biotechnology | 22 open or running | phase 2since Aug 4, 2026 | Mar 19, 2026 | none ahead |
| Sanofi | 20 open or running | phase 4since Apr 28, 2006 | Apr 28, 2006 | none ahead |
| Novartis | 10 open or running | phase 3since Aug 17, 2007 | Aug 17, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Jan 25, 2006.
- Jan 13, 2011Phase 3 study in TetanusGlaxoSmithKline · NCT01277705 · 806 enrolled
- Feb 10, 2011Phase 4 study in TetanusGlaxoSmithKline · NCT01294605 · 460 enrolled · Belgium, Netherlands, Spain
- Nov 21, 2012Phase 3 study in TetanusGlaxoSmithKline · NCT01738477 · 165 enrolled · United States
- Dec 21, 2012Phase 3 study in Meningococcal InfectionsGlaxoSmithKline · NCT01767376 · 692 enrolled · Dominican Republic, Germany, Korea, Republic of
- Nov 14, 2013Phase 3 study in DiphtheriaGlaxoSmithKline · NCT01988857 · 302 enrolled · Vietnam
- Jan 23, 2014Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02052596 · 935 enrolled · United States
- Feb 20, 2014Phase 4 study in Whooping CoughGlaxoSmithKline · NCT02072525 · 359 enrolled · Canada
- Feb 26, 2015Phase 4 study in Diphtheria-Tetanus-acellular Pertussis VaccinesGlaxoSmithKline · NCT02377349 · 688 enrolled · Australia, Canada, Czechia and more
- Oct 6, 2017Phase 3 study in DiphtheriaGlaxoSmithKline · NCT03311659 · 448 enrolled · Russian Federation
- May 20, 2019Phase 1 study in Tetanus Immunisation (Healthy Volunteers)Sanofi · NCT03958799 · 71 enrolled · Canada
- Oct 22, 2019Phase 2 study in Respiratory Syncytial Virus InfectionsGlaxoSmithKline · NCT04138056 · 509 enrolled · United States, Belgium, Canada
- Dec 10, 2021Phase 3 study in Respiratory Syncytial Virus InfectionsGlaxoSmithKline · NCT05169905 · 9 enrolled · United States
- Mar 19, 2026Changchun BCHT Biotechnology's first study: phase 1 study in Whooping CoughNew to Changchun BCHT BiotechnologyChangchun BCHT Biotechnology · NCT07492303 · 96 planned
- Aug 4, 2026Phase 2 study in Whooping CoughPhase 2 reachedChangchun BCHT Biotechnology · NCT07894055 · 420 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07894055Whooping Cough · China | 2 | Recruiting | Changchun BCHT Biotechnology | Sep 25, 2026 | 420 |
| NCT07492303Whooping Cough | 1 | Not yet recruiting | Changchun BCHT Biotechnology | Jul 10, 2026 | 96 |
| NCT05169905Respiratory Syncytial Virus Infections · United States | 3 | Completed | GlaxoSmithKline | Aug 3, 2022 | 9 |
| NCT04138056Respiratory Syncytial Virus Infections · United States, Belgium, Canada | 2 | Completed | GlaxoSmithKline | Feb 25, 2020 | 509 |
| NCT03958799Tetanus Immunisation (Healthy Volunteers) · Canada | 1 | Completed | Sanofi | Apr 6, 2021 | 71 |
| NCT03311659Diphtheria · Russian Federation | 3 | Completed | GlaxoSmithKline | Aug 31, 2018 | 448 |
| NCT02377349Diphtheria-Tetanus-acellular Pertussis Vaccines · Australia, Canada, Czechia and more | 4 | Completed | GlaxoSmithKline | Aug 14, 2017 | 688 |
| NCT02072525Whooping Cough · Canada | 4 | Completed | GlaxoSmithKline | Jun 2, 2015 | 359 |
| NCT02052596Herpes Zoster · United States | 3 | Completed | GlaxoSmithKline | Jun 16, 2015 | 935 |
| NCT01988857Diphtheria · Vietnam | 3 | Completed | GlaxoSmithKline | May 10, 2014 | 302 |
| NCT01767376Meningococcal Infections · Dominican Republic, Germany, Korea, Republic of | 3 | Completed | GlaxoSmithKline | Jan 16, 2014 | 692 |
| NCT01738477Tetanus · United States | 3 | Completed | GlaxoSmithKline | Apr 2, 2014 | 165 |
| NCT01294605Tetanus · Belgium, Netherlands, Spain | 4 | Completed | GlaxoSmithKline | Sep 2004 | 460 |
| NCT01277705Tetanus | 3 | Completed | GlaxoSmithKline | Apr 2002 | 806 |
| NCT01147900Tetanus · Belgium | 4 | Completed | GlaxoSmithKline | May 8, 2012 | 180 |
| NCT00835237Tetanus · United States | 3 | Completed | GlaxoSmithKline | Jul 23, 2009 | 1,332 |
| NCT00548171Tetanus · Australia | 4 | Completed | GlaxoSmithKline | Apr 30, 2008 | 203 |
| NCT00544271Tetanus · Australia | 4 | Terminated | GlaxoSmithKline | 720 | |
| NCT00518180Meningitis, Meningococcal · Costa Rica | 3 | Completed | Novartis | Apr 2008 | 1,620 |
| NCT00452686Diphtheria · China | 3 | Completed | GlaxoSmithKline | 660 | |
| NCT00406562Tetanus · China | 3 | Completed | GlaxoSmithKline | 30 | |
| NCT00385255Diphtheria · United States | 3 | Completed | GlaxoSmithKline | Feb 28, 2007 | 1,726 |
| NCT00346073Diphtheria · United States | 3 | Completed | GlaxoSmithKline | Mar 1, 2007 | 2,337 |
| NCT00319553Whooping Cough · United States | 4 | Completed | Sanofi | Oct 2008 | 647 |
| NCT00282295Tetanus · United States | 4 | Completed | GlaxoSmithKline | Aug 8, 2006 | 1,344 |
How it is read
Names in the registry
- “Boostrix™”, 6 entries
- “Boostrix”, 5 entries
- “Boostrix®”, 5 entries
- “Tdap vaccine”, 2 entries
- “Boostrix-US”, 1 entry
Conditions, from the studies’ own filings
- Tetanus, 9 studies
- Diphtheria, 7 studies
- Whooping Cough, 4 studies
- Respiratory Syncytial Virus Infections, 2 studies
- Herpes Zoster, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.